GMAB Genmab A/S

QT76

Latest market price

57.06

+0.57+1.01%

Overview Short InterestFilings

GMABQT76Genmab A/S·NASDAQ

Overview Short InterestFilings

57.06+1.01%

Loading chart...

Signal & projected range

QT Score upgradeHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

ONC-0.33%$370.33 RVMD+0.55%$191.31 ROIV-1.63%$36.91 UTHR+0.87%$598.72 INSM+0.89%$112.58 INCY+3.07%$120.39 ARGX-0.55%$892.87 ALNY-5.17%$165.00

Snapshot

Index	—	P/E	44.93	EPS (ttm)	1.27	Insider Own	—	Shs Outstand	614.90M	Perf Week	30.30%

Market Cap	35.09B	Forward P/E	32.53	EPS next Y	1.75	Insider Trans	—	Shs Float	587.09M	Perf Month	65.15%

Enterprise Value	38.84B	PEG	1.38	EPS next Q	0.37			Short Float	1.12%	Perf Quarter	98.95%

Income	788.00M	P/S	8.49	EPS this Y	-31.62%			Short Ratio	2.31	Perf Half Y	115.73%

Sales	4.13B	P/B	5.89	EPS next Y	48.76%	ROA	6.30%	Short Interest	6.60M	Perf YTD	85.26%

Book/sh	9.69	P/C	23.34	EPS next 5Y	32.60%	ROE	13.58%	52W High	59.97 -4.85%	Perf Year	97.10%

Cash/sh	2.44	P/FCF	40.47	EPS past 3/5Y	-42.87% -26.58%	ROIC	9.91%	52W Low	23.62 141.57%	Perf 3Y	96.42%

Dividend Est.	—	EV/EBITDA	31.83	Sales past 3/5Y	-36.45% -18.11%	Gross Margin	39.92%	Volatility	9.83% 5.66%	Perf 5Y	22.11%

Dividend TTM	—	EV/Sales	9.40	EPS Y/Y TTM	-85.11%	Oper. Margin	13.81%	ATR (14)	2.45	Perf 10Y	236.04%

Dividend Ex-Date	—	Quick Ratio	2.44	Sales Y/Y TTM	-68.25%	Profit Margin	8.17%	RSI (14)	87.57	Recom	2.28

Dividend Gr. 3/5Y	—	Current Ratio	2.46	EPS Q/Q	0.00%	SMA20	37.03%	Beta	0.73	Target Price	50.60

Payout	0.00%	Debt/Eq	0.88	Sales Q/Q	24.86%	SMA50	53.73%	Rel Volume	2.16	Prev Close	56.49

Employees	3,119	LT Debt/Eq	0.83	Earnings	Nov 05	SMA200	87.06%	Avg Volume	3.99M	Price	57.06

IPO Date	Jun 01, 2009	Option/Short	Yes / Yes	EPS/Sales Surpr.	51.66% 3.46%	Net Debt/EBITDA	3.08	Volume	8,625,805	Change	1.01%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Oct-29-26	Reiterated	HC Wainwright & Co.	Buy	$38 → $70
Oct-26-26	Upgrade	JP Morgan	Neutral → Overweight
Oct-20-26	Reiterated	Morgan Stanley	Equal Weight	$31 → $42
Oct-07-26	Reiterated	Guggenheim	Buy	$54 → $58
Oct-05-26	Reiterated	Guggenheim	Buy	$40 → $54
Jul-22-26	Reiterated	New Street		$43
Jul-22-26	Upgrade	TD Cowen	Hold → Buy
May-27-26	Reiterated	Truist Financial	Buy	$48 → $40
Apr-30-26	Reiterated	HC Wainwright & Co.	Buy	$39 → $38
Mar-26-26	Initiated	Wolfe Research	Outperform	$32

Latest News· Times ET

Oct-28-26

Oct-28-2605:30PM

Genmab A/S (GMAB) Discusses Phase III Cancer Data and Potential New Treatment Standards Transcriptseekingalpha.com

05:05PM

Genmab's Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launchesmarketbeat.com

01:44PM

Genmab Stock Hits 52-Week High - Here's Whybenzinga.com

01:21PM

Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%barrons.com

09:40AM

Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancerglobenewswire.com

Oct-26-26

Oct-26-2607:23PM

Petosemtamab Trial Results May Change The Case For Genmab StockYahoo

12:26PM

Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapyzacks.com

11:08AM

Genmab's Encouraging Oncology Data Boosts Investor Optimismbenzinga.com

07:46AM

Genmab Shares Jump After Positive Cancer Study Resultswsj.com

07:00AM

Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinomaglobenewswire.com

Oct-25-26

Oct-25-2607:00AM

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancerglobenewswire.com

Oct-24-26

Oct-24-2608:00AM

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancergurufocus.com

07:00AM

Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancergurufocus.com

Oct-23-26

Oct-23-2611:55AM

Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancerglobenewswire.com

Oct-20-26

Oct-20-2605:20AM

GENMAB A/S -SP ADR (NASDAQ:GMAB) Eyes Breakout as Technical Strength BuildsChartMill

Company

Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	4,131	3,723	21,526	16,474	—	—	—	—	—
Cost of Goods Sold Incl. D&A	288	309	985	226	—	—	—	—	—
Gross Profit	3,843	3,414	20,541	16,248	—	—	—	—	—
Selling, General and Administrative Excl. Other	727	602	3,790	3,297	—	—	—	—	—
Research and Development	1,782	1,560	9,748	7,630	—	—	—	—	—
Other Operating Expense	0	1	300	0	—	—	—	—	—
Operating Income	1,334	1,251	6,703	5,321	—	—	—	—	—
Interest Expense	269	61	120	27	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-159	15	2,581	343	—	—	—	—	—
Net Income Before Taxes	906	1,205	9,164	5,637	—	—	—	—	—
Income Taxes	118	241	1,320	1,285	—	—	—	—	—
Consolidated Net Income	788	964	7,844	4,352	—	—	—	—	—
Net Income From Continuing Operations	788	964	7,844	4,352	—	—	—	—	—
Net Income	788	964	7,844	4,352	—	—	—	—	—
EPS (Recurring)	1.28	1.55	12.14	6.60	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	1.28	1.55	12.14	6.60	—	—	—	—	—
EPS (Diluted)	1.27	1.54	12.14	6.60	—	—	—	—	—
EBITDA	1,220	1,337	9,697	6,001	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	44.93	20.00	1.72	4.82	—	—	—	—	—
Price To Sales Ratio	8.47	5.15	0.63	1.27	—	—	—	—	—
Gross Margin	93.03	91.70	95.42	98.63	—	—	—	—	—
Operating Margin	32.29	33.60	31.14	32.30	—	—	—	—	—
Net Margin	19.08	25.89	36.44	26.42	—	—	—	—	—
Shares Outstanding	613	622	646	659	—	—	—	—	—
Market Capitalization	34,978	19,158	13,482	20,983	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.